Terms: = Kidney tumors AND CCNE1, CCNE, 898, ENSG00000105173, P24864 AND Treatment
11 results:
1. Bioinformatic analysis highlights SNHG6 as a putative prognostic biomarker for kidney renal papillary cell carcinoma.
Liu Y; Cheng X; Xi P; Zhang Z; Sun T; Gong B
BMC Urol; 2023 Apr; 23(1):54. PubMed ID: 37004005
[TBL] [Abstract] [Full Text] [Related]
2. Silencing of long noncoding RNA MYLK-AS1 suppresses nephroblastoma via down-regulation of ccne1 through transcription factor TCF7L2.
Zhu S; Zhang J; Gao X; Tang X; Cui Y; Li D; Jia W
J Cell Physiol; 2021 Aug; 236(8):5757-5770. PubMed ID: 33438217
[TBL] [Abstract] [Full Text] [Related]
3. Influence of gene expression on survival of clear cell renal cell carcinoma.
Berglund A; Amankwah EK; Kim YC; Spiess PE; Sexton WJ; Manley B; Park HY; Wang L; Chahoud J; Chakrabarti R; Yeo CD; Luu HN; Pietro GD; Parker A; Park JY
Cancer Med; 2020 Nov; 9(22):8662-8675. PubMed ID: 32986937
[TBL] [Abstract] [Full Text] [Related]
4. Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed-dose regimen: What is the economic impact?
Bayle A; Besse B; Annereau M; Bonastre J
Eur J Cancer; 2019 May; 113():28-31. PubMed ID: 30965212
[TBL] [Abstract] [Full Text] [Related]
5. Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China.
Shi G; Park SH; Ren H; Xue M; Lu X; Dong P; Gao X
J Med Econ; 2018 Dec; 21(12):1150-1158. PubMed ID: 30134758
[TBL] [Abstract] [Full Text] [Related]
6. Avoidance of androgen deprivation therapy in radiorecurrent prostate cancer as a clinically meaningful endpoint for salvage cryoablation.
Ginsburg KB; Elshafei A; Yu C; Jones JS; Cher ML
Prostate; 2017 Oct; 77(14):1446-1450. PubMed ID: 28856702
[TBL] [Abstract] [Full Text] [Related]
7. Gene set enrichment analysis and ingenuity pathway analysis of metastatic clear cell renal cell carcinoma cell line.
Khan MI; Dębski KJ; Dabrowski M; Czarnecka AM; Szczylik C
Am J Physiol Renal Physiol; 2016 Aug; 311(2):F424-36. PubMed ID: 27279483
[TBL] [Abstract] [Full Text] [Related]
8. Radiofrequency ablation versus partial nephrectomy for clinical T1a renal-cell carcinoma: long-term clinical and oncologic outcomes based on a propensity score analysis.
Chang X; Liu T; Zhang F; Ji C; Zhao X; Wang W; Guo H
J Endourol; 2015 May; 29(5):518-25. PubMed ID: 25556579
[TBL] [Abstract] [Full Text] [Related]
9. A multi-institutional study of factors influencing the use of stereotactic radiosurgery for brain metastases.
Hodgson DC; Charpentier AM; Cigsar C; Atenafu EG; Ng A; Bahl G; Zadeh G; San Miguel J; Menard C
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):335-40. PubMed ID: 22704984
[TBL] [Abstract] [Full Text] [Related]
10. Inhibition of STAT1 sensitizes renal cell carcinoma cells to radiotherapy and chemotherapy.
Zhu H; Wang Z; Xu Q; Zhang Y; Zhai Y; Bai J; Liu M; Hui Z; Xu N
Cancer Biol Ther; 2012 Apr; 13(6):401-7. PubMed ID: 22262126
[TBL] [Abstract] [Full Text] [Related]
11. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
[TBL] [Abstract] [Full Text] [Related]
